FDA rejects Arena's obesity drug lorcaserin

The FDA has declined to approve Arena Pharmaceuticals' weight-loss drug lorcaserin, citing concern about the medicine's potential risks and "minimal" effectiveness. The agency asked for an independent review of a study demonstrating the growth of breast tumors in female rats treated with lorcaserin. "We will work with the agency to address the issues," CEO Jack Lief said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ